Vyvgart Sales Drive Argenx Q4, Shares Up 26.9% Over Past Year
Argenx SE’s shares delivered a 4.04% one-month return and a 26.86% 52-week gain after Vyvgart sales meaningfully exceeded expectations in Q4 2025, contributing significantly to Baron Health Care Fund’s 13.10% institutional-share gain. Vyvgart’s strong launches in generalized myasthenia gravis and CIDP and upcoming Phase 3 readouts for myositis and empasiprubart underpin bullish growth prospects.
1. Baron Health Care Fund Q4 Performance
Baron Health Care Fund’s institutional shares rose 13.10% in Q4 2025, outpacing the Russell 3000 Health Care Index’s 11.92% gain. Strong biotechnology selection, led by Argenx SE’s Vyvgart performance, was cited as a key contributor to this outperformance.
2. Vyvgart Sales Exceed Expectations
Vyvgart, Argenx’s FcRn inhibitor for autoimmune conditions, delivered sales that meaningfully exceeded investor estimates in Q4. Management and consulting neurologists highlighted robust uptake, particularly in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP).
3. Share Performance Metrics
Argenx SE shares returned 4.04% over the past month and 26.86% over the last 52 weeks through February 5, 2026. The stock closed at $820.31 per share, reflecting a market capitalization of $50.8 billion.
4. Pipeline and Growth Outlook
The company expects Vyvgart to expand into additional autoantibody-driven indications, with Phase 3 readouts for myositis and empasiprubart in multifocal motor neuropathy scheduled in the coming quarters. Investors remain positive on long-term growth due to the product’s launch momentum and a deepening clinical pipeline.